{"preliminary_commentary":{"by_channel":{"x_thread":8,"youtube":2,"podcast":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02471391\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["venetoclax","ibrutinib"]],"indication":"relapsed or refractory mantle cell lymphoma","name":"AIM","nct_id":"NCT02471391","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=aim-nct02471391. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"AIM","arms":[{"description":null,"label":"Ibrutinib + ABT-199","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2025-06","type":"ESTIMATED"},"conditions":["Mantle Cell Lymphoma"],"enrollment":{"count":37,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"ABT-199","otherNames":[],"type":"DRUG"},{"name":"Ibrutinib","otherNames":[],"type":"DRUG"}],"last_update":"2023-08-21","lead_sponsor":"Peter MacCallum Cancer Centre, Australia","official_title":"A Phase 2 Study of ABT-199 in Combination With Ibrutinib in the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma (AIM Study)","overall_status":"UNKNOWN","phases":["PHASE2"],"primary_completion_date":{"date":"2020-11-20","type":"ACTUAL"},"primary_outcomes":[{"measure":"Complete response measured using IWG at 16 weeks","timeFrame":"Measured at 16 weeks after commencement of treatment."}],"references":[{"citation":"Davis JE, Le LHH, Ludford-Menting M, Holzwart N, Handunnetti SM, Tam CS, Anderson MA, Ritchie DS, Koldej RM. Marginal zone lymphoma is associated with dysregulated T-cell immunity that is not altered by ibrutinib-venetoclax treatment. Blood Neoplasia. 2026 Jun 25;3(3):100260. doi: 10.1016/j.bneo.2026.100260. eCollection 2026 Aug.","pmid":"42540369","type":"DERIVED"},{"citation":"Handunnetti SM, Khot A, Blombery P, Burbury K, Thompson PA, Ritchie D, Hicks RJ, Burke G, Koldej R, Bressel M, Di Iulio J, Westerman DA, Lade S, Roberts AW, Seymour JF, Tam CS, Anderson MA. Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma. Blood Adv. 2026 Mar 10;10(5):1733-1742. doi: 10.1182/bloodadvances.2025016646.","pmid":"41380113","type":"DERIVED"},{"citation":"Handunnetti SM, Anderson MA, Burbury K, Thompson PA, Burke G, Bressel M, Di Iulio J, Hicks RJ, Westerman D, Lade S, Pott C, Agarwal R, Koldej R, Ritchie D, Dreyling M, Dawson MA, Dawson SJ, Seymour JF, Roberts AW, Tam CS. Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions. Blood. 2024 Aug 22;144(8):867-872. doi: 10.1182/blood.2023023388.","pmid":"38662991","type":"DERIVED"},{"citation":"Davis JE, Handunnetti SM, Ludford-Menting M, Sharpe C, Blombery P, Anderson MA, Roberts AW, Seymour JF, Tam CS, Ritchie DS, Koldej RM. Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy. Blood Adv. 2020 Oct 13;4(19):4849-4859. doi: 10.1182/bloodadvances.2020002810.","pmid":"33031542","type":"DERIVED"},{"citation":"Tam CS, Anderson MA, Pott C, Agarwal R, Handunnetti S, Hicks RJ, Burbury K, Turner G, Di Iulio J, Bressel M, Westerman D, Lade S, Dreyling M, Dawson SJ, Dawson MA, Seymour JF, Roberts AW. Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma. N Engl J Med. 2018 Mar 29;378(13):1211-1223. doi: 10.1056/NEJMoa1715519.","pmid":"29590547","type":"DERIVED"}],"start_date":{"date":"2015-07-22","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM)","url":"https://clinicaltrials.gov/study/NCT02471391"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/aim-nct02471391"}